Which of the following statements regarding the treatment of hypertension in pregnancy are true?
IPF Update: FIBRONEER-IPF Study of Nerandomilast Meets Primary End Point
The positive pivotal phase 3 trial results showed improved lung function with neradomilast vs placebo and will support BI's US and global NDA submissions.
Infectious Disease & Primary Care: A Conversation with IDWeek 2023 Chair
Listen to our latest podcast episode with Heather Yun, MD, for details on emerging pathogens, the role of primary care clinicians in the effort to rein in antimicrobial resistance, and more.
Novel Oral Antiobesity Drug Shown to Reduce Body Weight by up to 13% in First-In-Human Study
EASD 2024: Amycretin was also found to be safe and well tolerated in adults with obesity and without diabetes.
Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care
Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.
FDA Updates Felinzanetant Label Warnings After Report of Severe Liver Injury
FDA heightened label warnings about hepatic injury and increased the required frequency of liver function testing after initiation of fezolinetant.
Good Cardiovascular Health Early on May Offset Genetic Risk of Hypertensive Disorders of Pregnancy
New data shows that favorable CV health in the first trimester is associated with a 35% to 62% lower risk of HDP regardless of level of genetic risk.